TWO-YEAR EFFICACY AND SAFETY OF MIRIKIZUMAB FOLLOWING 104 WEEKS OF CONTINUOUS TREATMENT: INTERIM RESULTS FROM THE LUCENT-3 OPEN-LABEL EXTENSION STUDY

Bruce E. Sands  1     Geert R. D'Haens  2     David B. Clemow  3     Peter Irving  4     Jordan T. Johns  4     Theresa Hunter Gibble  4     Maria T. Abreu  5     Scott Lee  6     Tadakazu Hisamatsu  7     Taku Kobayashi  8     Marla C. Dubinsky  9     Severine Vermeire  10     Corey A Siegel  11     Laurent Peyrin-Biroulet  12     Richard Moses  12     Joe Milata  12     Vipin Arora  12     Remo Panaccione  13     Axel Dignass  14    
1 Icahn School of Medicine at Mount Sinai, New York, United States
2 Amsterdam University Medical Centers, Amsterdam, Netherlands
3 Eli Lilly and Company, Indianapolis, United States
4 Guy's and St. Thomas’ Hospitals, London, United Kingdom
5 University of Miami, Miller School of Medicine, Coral Gables, United States
6 University of Washington Medical Center, Seattle, United States
7 Kyorin University School of Medicine, Tokyo, Japan
8 Kitasato University Kitasato Institute Hospital, Minato-ku, Japan
9 Mount Sinai Hospital, Mount Sinai, New York City, United States
10 University Hospital Leuven, Leuven, Belgium
11 Dartmouth-Hitchcock Medical Center, Lebanon, United States
12 Nancy University Hospital, Vandoeuvre-les-Nancy, France
13 University of Calgary, Calgary, Canada
14 Agaplesion Markus Krankenhaus, Frankfurt/ Main, Germany

Topic
Endoscopy, IBD, Colorectal

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing